The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Regional · UK & Ireland · continued

MHRA statements, read directly posts 31–60

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

AL
aliquot_lineTL3Regular14 Nov 2025#31

Since MHRA statements keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.

29 likes 8mo
VS
v.stanescuTL215 Nov 2025 · edited#32
aliquot_line, post #31: Since MHRA statements keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it. Go to post

A referral pathway that worked eighteen months ago may not exist now. The archive keeps these posts and they are read as current.

If it helps: the failure mode here is usually boring rather than dramatic.

0 likes in reply to #31 8mo
FT
fr.translation_moTL2Translator · FR17 Nov 2025#33

The arithmetic in post #32 is right; the assumption feeding it is the part to check.

Correcting an out-of-date claim in this subcategory with a source and a date is more valuable than a new topic on the same question.

I looked this up rather than remembered it, which is the right order.

3 likes 8mo
EN
e.nilsenTL219 Nov 2025#34

Answering the question post #30 raises rather than the one it answers.

What I can speak to on MHRA statements is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.

10 likes 8mo
MH
m.haddadTL2Regular21 Nov 2025#35
m.almeida, post #29: Post #25 put the caveat in the right place and I want to underline it. The useful distinction on MHRA statements is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars. Go to post

Following this. I have the same question and no better information than the first post.

22 likes in reply to #29 8mo
KM
k.marchandTL223 Nov 2025#36
g.haaland, post #3: The arithmetic on MHRA statements is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it. Go to post

Post #34 and I disagree about the size of the effect, not about the direction.

Members outside these two jurisdictions reading this thread should note that none of it transfers, including the parts that sound general.

The evidence for this is thinner than the way I have phrased it suggests.

0 likes in reply to #3 8mo
LI
l.ibarraTL2Regular24 Nov 2025#37

Narrowing post #36, because the general version has more than one answer.

The failure mode on MHRA statements is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

1 like 8mo
AD
a.delgadoTL226 Nov 2025#38

MHRA statements is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.

6 likes 8mo
SS
s.stavrianosTL2Member28 Nov 2025 · edited#39
an.kirchner, post #21: I keep a log for MHRA statements specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it. Go to post

This follows post #36 rather than contradicting it.

Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.

15 likes in reply to #21 8mo
AV
a.villalobosTL230 Nov 2025#40

Worth separating two things that post #38 runs together.

Worth stating the null on MHRA statements before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.

30 likes 8mo
DS
dr_seongTL3Physician1 Dec 2025#41
m.haddad, post #35: Following this. I have the same question and no better information than the first post. Go to post

Adding what did not work for me on MHRA statements, since the failures never get written up and they are half the useful information.

25 likes in reply to #35 8mo
IA
i.almeidaTL23 Dec 2025#42

Useful. I had the fact and not the reason, which turns out to be the important half.

11 likes 8mo
OO
orbitrap_olaTL3Mass spectrometrist5 Dec 2025#43

Worth separating two things that post #39 runs together.

Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.

1 like 8mo
OV
o.vukovicTL27 Dec 2025#44

Reframing MHRA statements slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.

0 likes 8mo
SK
s.karlsen_rphTL3Pharmacist8 Dec 2025#45
e.nilsen, post #34: Answering the question post #30 raises rather than the one it answers. What I can speak to on MHRA statements is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know. Go to post

Something worth flagging about MHRA statements: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.

18 likes in reply to #34 8mo
MP
m.perrinTL210 Dec 2025#46

Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand your obligations.

Where I would look next, rather than where I would stop.

7 likes 8mo
DO
dr_okonkwoTL4 Moderator12 Dec 2025#47

Post #43 and I disagree about the size of the effect, not about the direction.

The bit of MHRA statements that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.

0 likes 8mo
FS
f.sjobergTL213 Dec 2025 · edited#48

Taking post #47 at face value and following it one step further.

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

0 likes 7mo
DF
d.fontaineTL215 Dec 2025#49
KS
k.salinasTL217 Dec 2025#50

If you are new and reading this thread for the answer to MHRA statements: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.

24 likes 7mo
SS
s.solbergTL218 Dec 2025#51
v.milanovi, post #1: MHRA statements, read directly Writing it up because I had to work it out twice and would rather nobody else did. Asking about MHRA statements directly, because I have read four threads on it and each answered a slightly different question. The version I want answered is the narrow one: given the method stated below, is the result… Go to post

An honest declaration on MHRA statements: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.

13 likes in reply to #1 7mo
G
GDashwoodTL3Regular20 Dec 2025#52

Date the claim and say whether it is the United Kingdom or Ireland. They are different regulatory jurisdictions and the answer is frequently different.

Someone will know this better than I do and I hope they say so.

27 likes 7mo
JT
j.teixeiraTL221 Dec 2025#53

Picking up post #50: that is the part I would want checked first.

Where a member reports a decision, the useful detail is the stated reason rather than the outcome, because the reason is what generalises.

0 likes 7mo
CV
c.vermeulenTL223 Dec 2025#54
NS
n.szaboTL225 Dec 2025#55
d.fontaine, post #49: Where I part company with post #47, and it is a narrow parting. Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI. Go to post

Confirming post #53 from a second method, which matters more than confirming it from a second person.

MHRA statements looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.

19 likes in reply to #49 7mo
ID
integrator_draftTL3Regular26 Dec 2025#56

Small methodological point on MHRA statements: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.

0 likes 7mo
YR
y.ramosTL228 Dec 2025#57

Where guidance distinguishes between indications, quoting the indication is essential. The same compound has different positions under different indications.

I would want a second opinion before relying on that.

2 likes 7mo
VK
v.klausenTL3Regular30 Dec 2025 · edited#58

Post #56 describes the usual case. This is about the unusual one.

The relevant national body publishes its decisions and its shortage notifications directly, and those are the primary sources rather than any secondary summary.

That is my reading. Someone else read the same page differently and was reasonable.

8 likes 7mo
LC
l.cabreraTL231 Dec 2025#59

I came in to disagree and I am leaving without a disagreement.

5 likes 7mo
AS
a.stephanopoulosTL3Regular2 Jan 2026#60
v.milanovi, post #1: MHRA statements, read directly Writing it up because I had to work it out twice and would rather nobody else did. Asking about MHRA statements directly, because I have read four threads on it and each answered a slightly different question. The version I want answered is the narrow one: given the method stated below, is the result… Go to post

Everything in post #56 holds. The case it does not cover is the one I have.

Correcting an out-of-date claim in this subcategory with a source and a date is more valuable than a new topic on the same question.

14 likes in reply to #1 7mo